@democratiCrayn 3 months ago
VNDA gets FDA approval for motion sickness drug, stock up 18%
VNDA gets FDA approval for motion sickness drug, stock up 18%
Vanda Pharmaceuticals (VNDA) received FDA approval for their drug tradipitant to prevent vomiting from motion sickness. They are branding it as Nereus. This is the first new pharmacological therapy for motion sickness in over 40 years.
The stock jumped 18% in after-hours trading on the news. Vanda is also testing this drug for other uses, including gastroparesis and nausea caused by GLP-1 weight loss drugs like Wegovy.
finance.yahoo.com
| VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains
@ProduceCut309 3 months ago
Big win for . First new motion sickness drug in decades is no small deal, and that 18% pop makes sense. If they can expand Nereus into GLP-1 nausea or gastroparesis, this approval could be just the start.
